MS TURNER SPECTRUM UCITS FUND

A SUB-FUND OF FUNDLOGIC ALTERNATIVES PLC, AN IRISH UCITS FUND

FUND OBJECTIVE AND INVESTMENT STRATEGY

The Sub-Fund's objective is to seek long-term capital appreciation through a diversified portfolio of long and short positions in global equity and equity-related securities belonging to various market sectors of the economy.

The Investment Manager is likely to invest the assets of the Sub-Fund in the following five Long/Short Sub-Portfolios (1) Consumer; (2) Financial Services; (3) Medical Sciences; (4) Titan; and (5) Resources and Infrastructure. Each of the Sub-Portfolio Managers seeks to generate positive returns with low volatility and preserve capital in declining markets.

The Spectrum Strategy is based on the philosophy that earnings drive stock prices. Turner takes long positions in companies whose fundamentals support earnings that will exceed market consensus expectations and short positions in those with deteriorating earnings fundamentals.

INVESTMENT MANAGER

Turner Investments, L.P., founded in 1990, is an employee-owned investment management firm based in Berwyn, Pennsylvania, USA. Our investment professionals have been identifying and analyzing growth companies around the globe for over 20 years. Our investment team is grouped into sector-focused research teams that perform fundamental research on companies of all market caps across the globe. This structure allows analysts to maintain coverage of the companies they follow throughout their lifecycle.

Turner Investments, L.P. manages long-only and long/short U.S., global, and international equity strategies for institutions and high net worth individuals.

FUND CHARACTERISTICS

Inception Date	28th December, 2012					
Total Assets (USD)	\$38 Million					
Base Currency	USD					
Domicile	Ireland					
Passporting Status	Italy, UK, Spain, Germany, France,					
	Switzerland					
Legal Structure	An Open-Ended Investment Company (OEIC)					
	Every day (except legal public holidays in the					
Dealing Day	United Kingdom or Ireland or days on which					
	the stock markets in London are closed)					
Subscription/ Redemption notice	12 midday Irish time on relevant dealing day					
Settlement	Subscription: Dealing Day +3					
Settlement	Redemption: Dealing Day +5					
Currency Share Classes Available	EUR / USD / GBP					
Investment Manager	Turner Investments L.P.					
Promoter & Distributor	Morgan Stanley & Co International plc					
Custodian	Northern Trust Fiduciary Services (Ireland) Ltd					
Administrator	Northern Trust International Fund					
Auministrator	Administration Services (Ireland) Ltd					
Auditor	Ernst & Young					

PERFORMANCE¹



The above figures refer to the past. Past performance is not a reliable indicator of future results.

HISTORICAL MONTHLY RETURNS

on sourced from Turner Investments

Share B1 (EUR)	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD*
2013	2.61%	-0.50%	0.51%	-0.49%	0.47%	-1.24%	1.88%	0.46%	1.65%	1.54%	0.07%	0.43%	7.57%
2014	1.31%	3.71%	-2.24%	-1.58%	1.21%	0.30%	-4.06%	3.98%	-0.99%				1.36%

INVESTMENT MANAGER COMMENTARY²

After negative performance in July and strong performance in August, equities declined again in September. Uncertainty over the impact of the end of bond purchasing by the U.S. Federal Reserve, coupled with stronger economic data in the U.S., have resulted in higher relative interest rates in the U.S. which led to sharp appreciation in the U.S. dollar. The concerns over inflationary pressures as a result of weaker currencies caused European and emerging markets to decline sharply. U.S. stocks followed these markets lower, with smaller companies, and high valuation companies declining the most.

For the month of September, two of the long/short Sub-Portfolio Managers generated positive results while three generated negative returns. The top contributor to performance was the Medical Sciences Sub-Portfolio Manager followed by Titan. The Financial Services, Consumer and Resources & Infrastructure Sub-Portfolio Managers generated negative returns for the month.

Top overall contributors to performance in September among our long positions were IGI Laboratories, AMAG Pharmaceuticals and Horizon Pharmaceuticals. Top detractors to overall performance in the long book were Retrophin, Intercept Pharmaceuticals and Louis XIII Holdings Limited.

As of 30 September 2014, the weightings of the five Sub-Portfolios Spectrum consists of were: Consumer, 18.85%; Financial Services, 17.8%; Medical Sciences, 19.94%; Resources & Infrastructure, 22.6%; and Titan, 20.81%.

The fund slightly decreased its overall gross and net exposure to approximately 184% and 50% respectively during the month. The gross exposure of the five underlying Sub-Portfolios varied throughout the month; at month's end the Medical Sciences Sub-Portfolio had the highest gross exposure, at approximately 214%. The Sub-Portfolio with the lowest relative gross exposure was the Financial Services one, with approximately 149% gross exposure.

As of 30 September 2014, the fund held a total of 167 positions long and 126 positions short.

*Discussion of substantial short positions in listed investments can affect market prices; therefore we do not discuss such information.

¹ Index information is included for illustration purposes only and is not intended to imply that the portfolio was similar to any index either in composition or element of risk

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the Fundlogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.



Morgan Stanley

Factsheet - September 30th, 2014

TOP HOLDINGS³

TOP 5 LONGS							
COMPANY / SECTOR	% of NAV						
HORIZON PHARMA, INC.	3.24%						
CUBIST PHARMACEUTICALS, INC.	2.41%						
IGI INC	2.27%						
MOODY'S CORPORATION	2.21%						
AMAG PHARMACEUTICALS INC.	2.08%						
	12.21%						

Source: Morgan Stanley

RISK METRICS⁴

EXPOSURE AND RISK	SUMMARY
	% of NAV
Long Exposure	123.3%
Short Exposure	-70.2%
Gross Exposure	193.5%
Net Exposure	53.2%
Annualised Volatility 5	6.6%
Absolute VaR ⁷	7.88%


	Number of Positions
No. of Longs	167
No. of Shorts	126

Source: Morgan Stanley

SECTOR ANALYSIS⁴ 40% 35% 20% 20% 18% 20% 16% 14% 10% 9% 8% 8% 8% 6% 6% 4% 2% 2% 0% 0% -1% -2% -4% -6% -9% -9% -10% -12% -12% -14% -20% Indices and Futures Hedges Consumer Consumer Staples Energy Financials Health Care Industrials Information Materials Discretionary Technology ■ Net Long Short

Source: Morgan Stanley

GEOGRAPHIC ANALYSIS⁴



³ Month-end data used. Exposure is delta adjusted, excludes market hedges

⁴ Month-end data used. Exposure is delta adjusted, includes market hedges

 $^{\rm 5}$ Volatility is computed as the standard deviation of the daily returns.

⁶ Mega Cap (>= 20 billion); Large Cap (>= 5 billion, < 20 billion); Mid Cap (>= 1 billion , < 5 billion); Small Cap (> 0, < 1 billion)


7 Var 99% - 20 days computed

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Ap ations for sl sub-fund of the F ring Documents Alternatives plc (the "Fund") should not be made without firs local jurisdiction which are available free of charge from Morg an offer to buy or sell any security or instrument or to particip Iting the F KIID, AI solely for information purposes and is not an offer to buy or sell or a solicitat ation at the end of this document. out first cons in vou This infor formation has been prepared solely se refer to important information at n of te in any pa gy. Plea

TOP 5 SHORTS								
COMPANY / SECTOR	% of NAV							
VALMONT INDUSTRIES INC.	-2.37%							
DEERE & COMPANY	-1.67%							
THE BOEING COMPANY	-1.24%							
AMAZON.COM, INC.	-1.19%							
AGRIUM INC.	-1.18%							
	-7.65%							

Source: Morgan Stanley

MARKET CAP ANALYSIS (EQUITIES)^{3,6}





Factsheet - September 30th, 2014

FUND SHARE CLASS DETAILS

Share Class			Performance					Fees					
	Ссу	Min Inv	Launch Date	NAV	MTD	YTD	LTD	ISIN	BBG	SEDOL	Mgmt	Perf.	TER ⁹
Class B1	EUR	1,000,000	28-Dec-12	1091.89	-0.99%	1.36%	9.19%	IE00B8L62K65	FMSTB1E ID	B8L62K6	1.0%	0%	1.4%
Class B2	EUR	1,000,000	28-Jan-13	1055.84	-1.03%	0.99%	5.58%	IE00B88P7K19	FMSTB2E ID	B88P7K1	1.5%	0%	1.9%

⁸Class B1 Shares (EUR) and Class B2 Shares are initial investor share classes. Therefore it is expected that Class B1 Shares and B2 Shares will only be available for subscription until such time as the net assets of the sub-fund reach \$20 million and \$70 million respectively, or such other amount as may be determined by the Directors from time to time in their absolute discretion.

⁹ Total Expense Ratio includes Management Fees and Promoter Fees. For share classes launched before 31 July 2013, the TER is based on the expenses for the year ending 31 July 2013. This figure may vary from year to year. Source: Morgan Stanley. NAV are computed by Northern Trust.

IMPORTANT INFORMATION

This document has been prepared by Morgan Stanley & Co International plc as a marketing document to inform Professional Investors and Eligible Counterparts about certain matters concerning the Fund. It has been prepared solely for informational purposes and does not seek to make any recommendation to buy or sell any particular security (including Shares in the Fund) or to adopt any specific investment strategy. Any use of this document by a financial intermediary is restricted to clients for whom the information in this document and an investment in Shares of the Fund has been considered to be suitable by that financial intermediary in view of that client's situation and purpose, subject always to the applicable regulatory standard. If such a client considers an investment in Shares of the Fund, she/he should always ensure that she/he has satisfied herself/himself that she/he has been properly advised by that financial intermediary about the suitability of an investment.

This financial promotion has been issued and approved in the UK by Morgan Stanley & Co International plc, 25 Cabot Square, Canary Wharf, London E14 4QA, authorized and regulated by the Financial Conduct Authority, for distribution to Professional Clients or Eligible Counterparties only and must not be relied upon or acted upon by Retail Clients (each as defined in the UK Financial Conduct Authority's rules). All of the information contained in this document relating to Turner Investments L.P. (the "Turner Information") is communicated by Turner Investments L.P. located at 1205 Westlakes Drive, Suite 100, Berwyn, PA 19312 USA, authorized and regulated by the Financial Conduct Authority. While the board of the Fund has overall responsibility for monitoring of the investment objective, policy and performance of the Fund, Morgan Stanley & Co International plc disclaims any and all liability relating to the Turner Information, including, without limitation, any express or implied representations or warranties for statements or errors contained in, and omissions from, the Turner Information.

This communication is a marketing communication; it has been prepared solely for information purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, Key Investor Information Document, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge at the address above. The Offering Documents contain material information not contained herein. In particular, the Prospectus contains details relating to the terms of investment and information regarding investment risks and conflicts of interest. Any representation to the contrary is not permitted. In the event of such offering, the information in this document will be superseded, amended and/or supplemented in its entirety by the Prospectus. You should not rely solely on the information contained herein. Including but not limited to the Turner Information. but should carefully read. the Offering Documents before making any investment decision.

The material contained herein has not been based on a consideration of any individual client circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley & Co International plc. It is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

No representation or warranty can be given with respect to the accuracy or completeness of the information, or with respect to the terms of any future offer of transactions conforming to the terms hereof. We do not undertake to update this information. Certain assumptions may have been made in the analysis that resulted in any information and returns/results detailed herein. No representation is made that any results/returns indicated would be achieved or that all assumptions in achieving these returns have been considered or stated. Changes to the assumptions may have a material impact on any results/returns detailed. Morgan Stanley and its affiliates disclaim any and all liability relating to this information, including without limitation any express or implied representations or warranties for statements contained in, and omissions from, this information. Additional information concerning the portfolio may be available upon request from the investment manager.

Although this report has been prepared using sources, models and data that Morgan Stanley ("MS") believes to be reasonably reliable, its accuracy, completeness or suitability cannot be guaranteed. Therefore, this information is supplied on an "AS IS" basis, and NO WARRANTY IS MADE AS TO ITS ACCURACY, COMPLETENESS, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto. All information contained herein is proprietary and is protected under copyright law.

The investment manager to the Fund may from time to time, at its sole discretion and out of its own resources, decide to rebate to Shareholders part or all of its investment management fee and/or performance fee. Any such rebates may be applied by issuing additional shares to shareholders or in cash. In addition to the information disclosed in the periodic reports of FundLogic Alternatives plc (the "Company"), the Company may, from time to time, make available to investors portfolio holdings and portfolio-related information in respect of one or more of the sub-funds including the Fund. Any such information will be available to all investors in the relevant sub-fund on request. Any such information will only be provided on a historical basis and after the relevant dealing day to which the information relates.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives pic (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your ocal jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.



RISK WARNING

Past performance is not a guarantee of future performance. The value of the investments and the income from them can go down as well as up and an investor may not get back the amount invested. There can be no assurance that the Fund will achieve its investment objectives.

Investments may be in a variety of currencies and therefore changes in rates of exchange between currencies may cause the value of investments to decrease or increase. Furthermore, the value of investments may be adversely affected by fluctuations in exchange rates between the investor's reference currency and the base currency of the investments.

Investments in derivative instruments carry certain inherent risks such as the risk of counter party default and before investing you should ensure you fully understand these risks. Use of leverage may also magnify losses as well as gains to the extent that leverage is employed.

These investments are designed for investors who understand and are willing to accept these risks. Performance may be volatile, and an investor could lose all or a substantial portion of his or her investment

SELLING RESTRICTIONS:

The Fund may only be offered and distributed to investors in accordance with all relevant local laws and regulations. The distribution of this presentation and the offering or purchase of interests in the Fund may be restricted in certain countries. This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations. It is the responsibility of any persons in possession of this document and any persons wishing to purchase interests in the Fund to inform themselves of, and to observe, all applicable laws and regulations of any relevant country.

For Investors in Hong Kong: This document is issued by Morgan Stanley Asia Limited ("Morgan Stanley") and has not been reviewed by the Securities and Futures Commission of Hong Kong. This document is only intended for and will only be distributed to persons that are professional investors as defined under the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong) and its subsidiary legislation as amended from time to time ("Professional Investors") and may not be circulated to the general public in Hong Kong. This Fund has not been authorised by the Securities and Futures Commission and may only be sold to Professional Investors Applications for shares in the MS TURNER SPECTRUM UCITS Fund should not be made without first consulting the current Prospectus, Key Investor Information Document, Annual Report and Semi-Annual Report ("Offering Documents") of the Fund.

This document has been prepared as information for Professional Investors in Hong Kong and it is not a recommendation to buy or sell any particular security or to adopt any investment strategy. Investors should exercise caution and seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley, and are based on matters as they exist as of the date of preparation and not as of any future date, and will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date hereof. No representation or warranty is given with respect to the accuracy or completeness of the information herein. This document is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation.

For Investors in Singapore: This material is being disseminated in Singapore by Morgan Stanley Asia (Singapore) Pte. The Fund is not authorised or recognised by the Monetary Authority of Singapore ("Authority") and shares in the Funds ("Shares") are not allowed to be offered to the Singapore retail public. This material which relates to the offer of Shares in the Funds is not a prospectus as defined in the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should consider carefully whether the investment is suitable for you.

This material has not been registered as a prospectus by the Authority, and the offer of the Shares is made pursuant to the exemptions under Sections 304 and 305 of the SFA. Accordingly, the Shares may not be offered or sold, nor may the Shares be the subject of an invitation for subscription or purchase, nor may this material or any other document or material in connection with the offer or sale, or invitation for subscription or purchase of the Shares be circulated or distributed, whether directly or indirectly, to any person in Singapore other than under exemptions provided in the SFA for offers made (a) to an institutional investor (as defined in Section 4A of the SFA) pursuant to Section 304 of the SFA, (b) to a relevant person (as defined in Section 305(5) of the SFA), or any person pursuant to an offer referred to in Section 305(2) of the SFA, and in accordance with the conditions specified in Section 305 of the SFA or (c) otherwise pursuant to. and in accordance with. the conditions of any other applicable provision of the SFA. Where the Shares are acquired by persons who are relevant persons specified in Section 305A of the SFA, namely:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within 6 months after that corporation or that trust has acquired the Shares pursuant to an offer made under Section 305 of the SFA except:

(1) to an institutional investor or to a relevant person as defined in Section 305(5) of the SFA, or which arises from an offer referred to in Section 275(1A) of the SFA (in the case of that corporation) or which arises from an offer that is made on terms that such rights or interest in that trust are acquired at a consideration of not less than \$\$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets (in the case of that trust); (2) where no consideration is or will be given for the transfer; or

(3) where the transfer is by operation of law.

Any offering of the Shares in Singapore would be through Morgan Stanley Asia (Singapore) Pte., an entity regulated by the Authority.

For Investors in Australia: This document is not an offer document under Chapter 6D of the Australian Corporations Act 2001, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of an offer document under Chapter 6D of the Corporations Act. Accordingly: (i) the offer of shares under this document is only being made in Australia to "Sophisticated Investors" within the meaning of Section 708(8) of the Corporations Act or "Professional Investors" within the meaning of Section 708(11) of the Australian Corporations Act, in each case who are "wholesale clients" for the purposes of section 761G(7) of the Corporations Act; (ii) this document is being made available in Australia only to such persons; and (iii) each applicant for shares in Australia represents that the applicant is such a person and, unless permitted under the Corporations Act, agrees not to sell or offer for sale within Australia any of the shares issued to the applicant within 12 months after their issue to the applicant under this document. Offers and issues of shares under this document in Australia are being made pursuant to an arrangement with Morgan Stanley Australia Limited.

For Investors in Switzerland: The representative and paying agent of FundLogic Alternatives plc, an Irish UCITS fund, in Switzerland is BNP PARIBAS Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich. The prospectus and the key investor information documents for Switzerland, the articles as well as the annual and semi-annual reports of FundLogic Alternatives plc may be obtained free of charge from the representative in Switzerland

This communication or any portion hereof, may not be reprinted, resold or redistributed without the prior written consent of Morgan Stanley.

Copyright © by Morgan Stanley 2014, all rights reserved.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the Fundi Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitati an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document. TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundL